Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer

Figure 2

Susceptibility of HER2/ neu positive and negative tumor cell lines to α-TEA + anti-HER2/ neu antibody. MMC (HER2/neu +) or ANV (Her2/neu -) cells were allowed to adhere overnight. MMC and ANV cells were then treated with 20 μg/mL of anti-HER2/neu antibody (7.16.4), 20 μg/mL of mouse IgG2a antibody (isotype) or 20 μM of Vα-TEA. MDA-MB-453 (HER2/neu +) and MDA-MB-231 cells were treated with 10 μg/mL (MDA-MB-453) or 20 μg/mL (MDA-MB-231) trastuzumab or rituximab (isotype) or 10 μM Vα-TEA. After a 5 day exposure, cell survival was determined by MTT assay. Combined results from two to three independent experiments are expressed as mean percentage ± SD of untreated cells (isotype) cells.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us